By NextBestFitRequire timely U.S. launch as a condition of market access
Link favorable pricing to launching in the U.S. promptly.
Draft decision:RejectedConfidence: low · not yet reviewed
Hard to enforce.
Review ledgerHow this path connects
This path
Require timely U.S. launch as a condition of market access
Concrete changes if chosen
What would actually have to change in law, agencies, payment rules, or systems.
- Tie favorable pricing to prompt U.S. launch
Effects
Each effect has its own page: the evidence, the case that it is or isn't a real cost, and whom it affects.
What it fixes
- Price limits can cause shortages, launch delays, or exits
Linking favorable pricing to prompt domestic launches uses a simple rule to prevent launch delays.
- Slower access to new drugs and technology
Making favorable prices conditional on prompt launches helps prevent delays in access to new products.
What it creates or worsens
- Requires difficult enforcement
Enforcing the link between favorable pricing and prompt launches is difficult.
- Faces political, industry, or legal opposition
Conditioning favorable pricing on prompt launches can face legal challenges.
Who's affected
Who gains
- People with ongoing or specialist care needs
- Price limits can cause shortages, launch delays, or exits: Low price limits may reduce access to products and services through shortages or exits.
- Slower access to new drugs and technology: Strict value assessment can delay or refuse new therapies.
- Drug and device makers
- Slower access to new drugs and technology: Lower prices reduce research returns for biotech workers and investors.
Who loses
- Taxpayers and public budgets
- Price limits can cause shortages, launch delays, or exits: Low price limits reduce spending in the short term.
- Slower access to new drugs and technology: Strict value assessment lowers payment for new products in the short run.
- Health insurers, brokers, and their shareholders
- Slower access to new drugs and technology: Strict value assessment lowers payment for new products in the short run.
- Drug and device makers
- Requires difficult enforcement: Enforcing the link between favorable pricing and prompt launches is difficult.
Where it has been tried
- N/A: Proposed in policy literature; not implemented.